Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Amgen

Which of these elite biotechs is the better buy right now?

Biogen vs. Amgen

Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.

Biogen Reports Interim Phase III Data on Diroximel Fumarate

In the latest trading session, Biogen (BIIB) closed at $223.40, marking a -0.95% move from the previous day.

Biogen (BIIB) Dips More Than Broader Markets: What You Should Know

Bristol-Myers

Celgene

Roche Holding AG

Celgene's (CELG) Revlimid in combination with a rituximab product gets FDA approval for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma.

Celgene's Revlimid-Rituximab Combo Gets FDA Nod for Lymphoma

Ionis Pharma

Novartis

Novartis just got Zolgensma approved for spinal muscular astrophy, and it will compete with Spinraza.

Rent-A-Gene With Biogen's Spinraza, Or Buy-A-Gene With Novartis' Zolgensma

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock?

Biogen (BIIB) Down 0.3% Since Last Earnings Report: Can It Rebound?

Biogen urged shareholders on Monday to reject a mini-tender offer from TRC Capital Corporation for up to 500,000 shares of Biogen stock.

Biogen Urges Shareholders To Reject Low-Ball Mini-Tender Offer

Biogen Inc.  on Monday advised shareholders to reject a mini-tender offer from TRC Capital which it dismissed as below the market price of its stock.

Biogen urges shareholders to reject 'below-market' mini-tender offer from TRC Capital

Biogen and Ionis just reported exciting data on a potential treatment for ALS, and are moving to Phase III.

Biogen's ALS Treatment Is Exciting, But Market Is Microscopic

Biogen has yet to recover after discontinuing its drug study for Alzheimer's disease.

Why Biogen Could Be A Buy At These Levels

First-quarter sales were up 11%, but future growth is less certain.

Biogen Looks to 23 Clinical Programs for Growth

AbbVie

Gilead Sciences

5 extremely cheap healthcare names with possible 30-50% upside potential.

5 Stocks To Own As Healthcare Bottoms

Biogen Inc. (BIIB) CEO Michel Vounatsos on Q1 2019 Results - Earnings Call Transcript

Biogen on Wednesday beat Wall Street estimates for quarterly profit, but failed to ease investor concerns about long-term growth after it recently shelved the development of an Alzheimer’s drug.

Biogen dips as strategy post Alzheimer’s setback fails to impress

ARK Genomic Revolution Multi-Sector ETF

VanEck Vectors Biotech ETF

First Trust NYSE Arca Biotechnology Index Fund

iShares Nasdaq Biotechnology ETF

Direxion Daily S&P Biotech Bull 3X Shares

Regeneron Pharmaceuticals

SPDR S&P Biotech ETF

When the stock market is hitting record highs, it’s important to remember that it’s really a market of stocks rather than a stock market. Not all companies are created equal. Nor are all sectors.

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.

Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales 

Biogen (BIIB) beat estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.

Biogen (BIIB) Q1 Earnings & Sales Beat Estimates

Shares of Biogen were up 1.8% in premarket trade Wednesday after the company reported revenue that beat estimates and earnings that were in line with what Wall Street had expected

Biogen stock up 1.8% in premarket trade after revenue beat

Biogen earnings and sales modestly beat Q1 views for the biotech giant.

Biogen Earnings, Sales Top After Alzheimer's Setback

These two drug stocks have been the industry's biggest losers this year. Which is the better buy now?

Better Buy: Biogen vs. AbbVie

Biogen is facing down troubles that could create value if resolved.

Sometimes opportunity comes in the shape of trouble: Biogen

Biogen (BIIB) closed at $232.37 in the latest trading session, marking a -0.91% move from the prior day.

Biogen Dips More Than Broader Markets

Which stock wins in a battle of two big biotechs?

Better Buy: Gilead Sciences vs. Biogen Inc.

Biogen’s MS franchise is facing several risks, including new launches

Raymond James: Biogen's Business Appears Fragile, Faces Many Headwinds

Biogen’s Alzheimer’s aducanumab failure heaps on more evidence that beta amyloid plaque is an effect of Alzheimer’s rather than the cause.

News for Biogen Stock (BIIB)